StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a report issued on Saturday morning. ALNY has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an outperform rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals […] Read this story
